Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as its primary route of elimination is biliary/fecal, requiring no renal dose adjustments.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use is generally not recommended in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required regardless of GFR or end-stage renal disease.
* **Hepatic Impairment:** No dose adjustment required; however, caution is advised in severe hepatic impairment due to limited clinical experience.
## Contraindications
* Hypersensitivity to linagliptin or any component of the formulation.
* History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to DPP-4 inhibitors.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with sulfonylureas or insulin).
* **Serious:** Acute pancreatitis, bullous pemphigoid, severe joint pain (arthralgia, may occur months after starting), and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy; increase monitoring of glycemic control if co-administration is unavoidable.
* **Insulin/Insulin Secretagogues:** Risk of hypoglycemia is increased. Consider dose reduction of the secretagogue or insulin when initiating linagliptin.
## Monitoring
* **Hemoglobin A1c:** Typically every 3–6 months.
* **Blood Glucose:** Periodic self-monitoring per clinical guidelines.
* **Signs/Symptoms of Pancreatitis:** Persistent, severe abdominal pain that may radiate to the back, with or without vomiting.
* **Skin Integrity:** Monitor for blistering or erosions suggestive of bullous pemphigoid.
## Clinical Pearls
* Linagliptin is weight-neutral and does not cause significant weight gain.
* It does not require dose adjustments based on renal function, making it a preferred DPP-4 inhibitor in chronic kidney disease patients.
* If pancreatitis is suspected, discontinue immediately and do not restart.
* Not indicated for the treatment of Type 1 diabetes or diabetic ketoacidosis.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information can change. Always verify specific dosing, safety data, and contraindications via the latest manufacturer prescribing information or clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
